| |||||||||

Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Total Revenues | 4.62B | 6.63B | 9.28B | 11.7B | 13.4B | |||
| Gross Profit | 3.66B | 5.99B | 8.51B | 10.6B | 12.3B | |||
| Operating Income | 0 | 0 | 3.15B | 4.23B | 5.33B | |||
| Net Income | 785M | 1.28B | 2.11B | 2.77B | 3.43B | |||
| Gross Margin | 0% | 0% | 0% | 0% | 87% | |||
| Number of Drugs in Phase I | 0 | 0 | 0 | 0 | 5.00 | |||
| Number of Drugs in Phase II | 0 | 0 | 0 | 0 | 11.0 | |||
| Number of Drugs in Phase III | 0 | 0 | 0 | 0 | 11.0 | |||
| Number of Patents | 0 | 0 | 0 | 0 | 11.0 | |||
| R&D/Sales Ratio | 0% | 0% | 0% | 0% | 20.9% | |||
| Research and Development Expense | 0 | 0 | 0 | 0 | 2.80B | |||
| ||||||